{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:44:34Z","timestamp":1790743474975,"version":"4.1.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","award":["Institutional start-up funding"],"award-info":[{"award-number":["Institutional start-up funding"]}],"id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted utilizing PubMed and MEDLINE databases, applicable published abstracts, and ongoing studies from ClinicalTrials.gov between January 1, 1981, and September 3, 2020. Keywords included sacituzumab govitecan (-hziy), IMMU-132, Trop-2 (trophoblast cell-surface antigen 2), and TACSTD2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All English-language trials involving sacituzumab govitecan for mTNBC were included and discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Sacituzumab govitecan is an antibody-drug conjugate targeted for Trop-2 and conjugated to the topoisomerase-1 inhibitor SN-38. It was granted accelerated Food and Drug Administration approval based on a phase I\/II single-arm, multicenter study (n = 108), which reported an overall response rate of 33.3% and median duration of response of 7.7 months (95% CI = 4.9-10.8 months). Common adverse reactions include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, abdominal pain, and respiratory infection. A confirmatory, randomized phase III clinical trial is ongoing (NCT02574455).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>This review covers the efficacy, safety, and clinical use of sacituzumab govitecan, a third-line drug with activity in mTNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Sacituzumab govitecan is a novel targeted treatment with promising activity in mTNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020966548","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:30:24Z","timestamp":1602905424000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":56,"title":["Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0052-4106","authenticated-orcid":false,"given":"John M.","family":"Seligson","sequence":"first","affiliation":[{"name":"Nova Southeastern University, Clearwater, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1383-1279","authenticated-orcid":false,"given":"Alexandra M.","family":"Patron","sequence":"additional","affiliation":[{"name":"University of Florida, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Berger","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-3792","authenticated-orcid":false,"given":"Nathan D.","family":"Seligson","sequence":"additional","affiliation":[{"name":"University of Florida, Jacksonville, FL, USA"},{"name":"Nemours Children\u2019s Specialty Care, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"bibr1-1060028020966548","doi-asserted-by":"publisher","DOI":"10.4137\/BCBCR.S23794"},{"key":"bibr2-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9331-1"},{"key":"bibr3-1060028020966548","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0131"},{"key":"bibr4-1060028020966548","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25615"},{"key":"bibr5-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.8297"},{"key":"bibr6-1060028020966548","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"bibr7-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00540"},{"key":"bibr8-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2476-0033"},{"key":"bibr9-1060028020966548","unstructured":"US Food and Drug Administration. FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments. Published April 22, 2020. Accessed June 5, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments#:~:text=Trodelvy%20was%20granted%20accelerated%20approval,and%20describe%20Trodelvy\u2019s%20clinical%20benefit"},{"key":"bibr10-1060028020966548","doi-asserted-by":"publisher","DOI":"10.7908\/C11G0KM9"},{"key":"bibr11-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.8.5147"},{"key":"bibr12-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7"},{"key":"bibr13-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09866-x"},{"key":"bibr14-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.36"},{"key":"bibr15-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.1075"},{"key":"bibr16-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.02.017"},{"key":"bibr17-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00223"},{"key":"bibr18-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213"},{"key":"bibr19-1060028020966548","unstructured":"Trodelvy. Package insert. Immunomedics Inc; 2020."},{"key":"bibr20-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0670"},{"key":"bibr21-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30789"},{"key":"bibr22-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-2939"},{"key":"bibr23-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115"},{"key":"bibr24-1060028020966548","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27342"},{"key":"bibr25-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz014.041"},{"key":"bibr26-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5027"},{"key":"bibr27-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1004"},{"key":"bibr28-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.354"},{"key":"bibr29-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0933"},{"key":"bibr30-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1894"},{"key":"bibr31-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.3_suppl.703"},{"key":"bibr32-1060028020966548","unstructured":"Lexicomp\u00ae. Sactituzumab govitecan. Accessed June 13, 2020. https:\/\/www.uptodate.com\/contents\/sacituzumab-govitecan-drug-information?search=sacituzumab%20govitecan&source=panel_search_result&selectedTitle=1~6&usage_type=panel&kp_tab=drug_general&display_rank=1#F54407926"},{"issue":"122","key":"bibr33-1060028020966548","first-page":"1","author":"Fryar CD","year":"2018","journal-title":"Natl Health Stat Report"},{"key":"bibr34-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"bibr35-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"bibr36-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"bibr37-1060028020966548","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1210-4"},{"key":"bibr38-1060028020966548","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6042187"},{"key":"bibr39-1060028020966548","unstructured":"ASCENT-study of sacituzumab govitecan in refractory\/relapsed triple-negative breast cancer (ASCENT). ClinicalTrials.gov Identifier: NCT02574455. Updated August 27, 2020. Accessed October 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02574455?term=NCT02574455&draw=2&rank=1"},{"key":"bibr40-1060028020966548","unstructured":"US Food and Drug Administration. Application number:761115Orig1s000. Administrative and correspondence documents. Accessed June 5, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761115Orig1s000AdminCorres.pdf"},{"key":"bibr41-1060028020966548","unstructured":"Immunomedics, Inc. Accessed June 5, 2020. https:\/\/www.immunomedics.com\/news-and-events\/fda-grants-accelerated-approval-for-immunomedics-trodelvy-in-previously-treated-metastatic-triple-negative-breast-cancer"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020966548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020966548","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020966548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:57Z","timestamp":1777374957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020966548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/1060028020966548"],"URL":"https:\/\/doi.org\/10.1177\/1060028020966548","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]}}}